EDITORIAL / WHO KEEPS THE RECORD
About Wolverine Buy and the BPC-157 TB-500 Record
A field record that reads the published literature on the Wolverine blend and carves it into a sourced, plain account.
What this site is
Wolverine Buy keeps a field record on the BPC-157 TB-500 blend and its two constituents. It reads the peer-reviewed research and logs it to source: each finding marked to the studies it derives from, each gap — above all the absence of any controlled combination trial — left visible rather than smoothed over. Where a claim is quantitative, it cites a study you can open and read. Nothing is dispensed from this record and nothing is sold; there is no clinic behind it, no prescriber, and no clinical staff — only the literature, carved down to what it actually establishes.
On the name
The 'Buy' in the domain is framing, not a service. This site supplies nothing and sells nothing. Read 'buy' as acquiring the record — gathering and provenancing the literature — rather than acquiring a substance. There is no checkout, no pricing, no vendor tie, and no route to obtaining either peptide.
'Wolverine' is the research-community nickname for the BPC-157 + TB-500 pairing. The record uses it because that is what the literature and the forums call the blend — not because the site is tied to any product, brand, or character of the name. The terms it actually indexes are BPC-157 and TB-500.
How we read the evidence
Our standard is the published record. We summarize what studies measured, in which species, at which dose, by which route — and we attribute every figure. We do not translate animal-model parameters into human guidance, and we do not present the community's fixed-ratio vials or loading protocols as validated dosing, because no controlled trial supports them.
We also keep the regulatory record current and sourced, including the FDA 503A status of both constituents and their appearance on the July 2026 Pharmacy Compounding Advisory Committee agenda. We report present-tense regulatory facts and cite FDA directly; we do not assert any future FDA decision as a certainty. The aim is a record a reader can trust precisely because it shows its sources and marks its limits.